



United States Department of

**Health & Human Services**

Office of the Assistant Secretary for Preparedness and Response



# ***CBRN Vaccine Programs***

Eric Espeland, Ph.D.

Acting Chief, Vaccine Branch

**BARDA Industry Day**

**October 15-17 2014**

*ASPR: Resilient People. Healthy Communities. A Nation Prepared.*



# Smallpox Vaccine Program



Overarching: Maintain preparedness levels, addressing the needs of at risk individuals with compromised immune system or with atopic dermatitis during a smallpox emergency

## Near-term objectives

1. Stockpile maintenance of liquid frozen IMVAMUNE
2. Completion of activities for licensure of liquid frozen IMVAMUNE

## Future objectives

1. Continue development of Freeze Dried IMVAMUNE to allow for potential transition to this product

**Note: No additional vaccine development programs are planned for smallpox**



# Anthrax Vaccine Program



Overarching: Expand BioThrax utility and pursue licensure of next generation vaccine(s) that provide equivalent protection with fewer doses at potentially lower cost

**Near-term Objectives** – Focus on enhancements to BioThrax®

1. Label expansion for PEP
2. Expansion of domestic manufacturing capacity

## **Next Generation Vaccines**

1. Continue to invest in development of rPA vaccine candidates
  - Portfolio down-selected from 3 to 2 candidate vaccines in 2014
2. Adeno-vectored, nasally-delivered anthrax vaccine candidate



# VHF Vaccine Program



## Near-term Objectives

1. BARDA is currently working with PHEMCE partners to maximize funding resources towards accelerating promising Ebola vaccine candidate products into Phase 1 clinical studies.

## Future Objectives

1. Develop promising vaccine candidates against Ebola and Marburg
  - Objective to advance projects through end of Phase 2 development
  - Please see CBRN BAA Area of Interest #1 for information on minimum technical requirements for consideration

# Questions

